The NUTRIMUM trial was the first RCT specifically designed to assess the efficacy and safety of a broad-spectrum micronutrient formula on symptoms of antenatal depression and global functioning in an unmedicated pregnant cohort. Secondary analysis and follow-up studies also investigated both maternal and infant birth outcomes and post-partum health. Broad-spectrum micronutrients significantly improved overall clinician-rated and self-rated depression symptoms. Sleep quality and overall functioning improved. Micronutrients significantly reduced serum homocysteine and the risk of postpartum hemorrhaging for the mother and the need for resuscitation in the infants. The risk of preterm birth (more common in depressed mothers) was mitigated. In the first month of life infants exposed to broad-spectrum micronutrients in-utero markedly outperformed infants from similarly depressed mothers taking pharmaceutical antidepressants on 6 of 7 measures and even significantly outperformed infants from healthy control mothers on 3 of 7 measures. The depression rate at 6 months postpartum in the cohort of women who had taken broad-spectrum micronutrients during pregnancy was equal to the population average - a large reduction from expected rates for women with antenatal depression. There was no statistically greater emergence of adverse effects reported by participants in the micronutrient group compared with the placebo group.
Sponsored by Hardy Nutritionals.
%20(1).jpg)
%20(1).jpg)
%20(2)%20(2).png)
%20(1).jpg)
.png)
%20(1).png)
.jpg)
%20(1).jpg)

%20(2).png)

.jpg)
.jpg)
.png)
.jpg)


.webp)
.png)

.jpg)

.jpg)

.jpg)

.jpg)
.jpg)
.jpg)
.png)

.png)
.jpg)
.jpg)



.png)
-min%20(1)%20(1)-4500x4500.jpg)
.png)
.jpg)
.jpg)
.jpg)

.jpg)


.png)


.png)

.png)

.jpg)

%20(1).png)


.png)
.jpeg)
.png)
.jpg)
.png)
%20(1).jpg)
.jpeg)
.jpg)
.png)
-min.jpeg)

.jpg)
.png)
.jpeg)